百奥泰2025年净亏损3.36亿元

Core Viewpoint - Baotai reported a revenue of 934 million yuan for 2025, marking a year-on-year increase of 25.64%, while the net loss attributable to the parent company was 336 million yuan, an improvement from a net loss of 510 million yuan in the previous year [1] Group 1: Financial Performance - The company achieved an operating revenue of 934 million yuan in 2025, reflecting a growth of 25.64% compared to the previous year [1] - The net loss attributable to the parent company was 336 million yuan, which is an improvement from the net loss of 510 million yuan in the same period last year [1] Group 2: Market Expansion - Baotai actively expanded its market during the reporting period, with sales of Adalimumab injection (Geleli®) and Tocilizumab injection (Shiruili®) steadily increasing compared to the previous year [1] - The company launched Ustekinumab injection (STARJEMZA®) in the United States during the reporting period, contributing to growth in licensing income and sales revenue [1]